MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Common Stock · Q3 FY2026 · quarter ended Sep 2026
Common stock broadly unchanged from a year ago
Common stock stood at $6K at the end of Q3 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +81.7% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 6K USD
- Year-over-year change
- +20.0%
- 3-year CAGR
- +81.7%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6K | +20.0% |
| FY2024 | 2024-12-31 | 5K | +400.0% |
| FY2023 | 2023-12-31 | 1K | +0.0% |
| FY2022 | 2022-12-31 | 1K | — |
Common Stock vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.0% is the 6th highest of 8, against a peer median of +7.6%.
- Common stock amounts to 0.0% of total assets for MBX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €8.91M EUR | +7.6% | +2.7% | 0.4% | |
| Mar 2026 | $491K USD | +0.0% | -0.3% | 0.2% | |
| Sep 2026 | $70K USD | +4.5% | +6.2% | 0.0% | |
| Mar 2026 | $18K USD | +12.5% | +6.7% | 0.0% | |
| Mar 2026 | $13K USD | +62.5% | +30.1% | 0.0% | |
| Mar 2026 | $7K USD | +75.0% | +32.6% | 0.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $6K USD | +0.0% | +81.7% | 0.0% |
| Jun 2026 | $1K USD | +0.0% | +0.0% | 0.0% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding MBX) | — | +7.6% | +6.2% | 0.0% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.